Antibiotic-induced neuropathy …

Louis H Weimer MD

Peripheral Neuropathies

Updated 12.24.2023
Released 08.18.2004
Expires For CME 12.24.2026

Antibiotic-induced neuropathy

Author: Louis H Weimer MD

See Contributor Disclosures

Antibiotic-induced neuropathy

In This Article

Quick Link

Introduction

Overview

Antibiotic-induced neuropathy is a rare complication of several antimicrobial agents. In this article, the author discusses antibiotics that have been associated with peripheral neuropathy, focusing on those in general use and with the most established associations, and detailing the possible underlying pathophysiologic mechanisms leading to neuropathy. In most cases, the antibiotics result in a predominantly sensory axonopathy with a “dying back” of distal segments, and patients improve after the drug is discontinued.

Historical note and terminology

Although the Egyptians may have been the first to appreciate the antibiotic properties of some living matter when they applied moldy bread to wounds, and Sir Alexander Fleming discovered penicillin in 1928 and showed that it was active against Staphylococcus in culture, it wasn’t until Rene Dubos isolated tyrothricin from the soil microbe Bacillus brevis in 1939 that an antibiotic was isolated and used successfully to treat human disease.

The term antibiotic derives from the Greek, meaning “against life.” Strictly speaking, an antibiotic is a substance that is produced by one microorganism that is able to inhibit the growth or kill other microorganisms. More generally, the term is used to refer to any naturally produced, semi-synthetic, or synthetic compound that acts against microorganisms, and includes antibacterials, antifungals, antiprotozoals, and anthelminthics. Antivirals can be loosely considered antibiotics, and the only members of that class associated with significant peripheral neuropathy are the nucleoside analogs, used against HIV-1, which characteristically cause a distal symmetric dysesthetic sensory neuropathy, and podophyllin resin, which is used to treat warts caused by human papilloma virus and is associated with a sensory and autonomic neuropathy; neither of these will be addressed here.

Several antibiotics are associated with peripheral neuropathy. With some notable exceptions, these toxic effects are rare compared to the relatively high incidence of neuropathy associated with antiretroviral drugs and antineoplastic agents. Despite widespread antibiotic use, most of the associations are based on relatively few case reports, and on fewer detailed animal studies to support an underlying pathogenic mechanism. The essential basis of a connection relies at a minimum on a temporal association with drug intake, followed by symptomatic stabilization, improvement or resolution after stopping the drug. Table 1 lists those antimicrobials that have been associated with peripheral neuropathy. This review will cover antimicrobials that are in more general use and those with well-established associations. Antimicrobials (which have been associated solely with damage to cranial nerves or their end organs), such as the aminoglycosides (which are oto- and vestibulotoxic) and vancomycin (which is vestibulotoxic) are not covered. Suramin, which is not approved in the United States but which is used elsewhere as an antiprotozoal agent, and is under investigation as an antineoplastic drug, is covered.

Table 1. Antimicrobials Associated with Peripheral Neuropathy

• Chloramphenicol
• Chloroquine
• Clioquinol
• Dapsone
• Ethambutol
• Fluoroquinolones
• Griseofulvin
• Isoniazid
• Linezolid
• Mefloquine
• Metronidazole
• Nitrofurantoin
• Podophyllin resin
• Suramin

Biological basis

Etiology and pathogenesis

Most of these agents cause a length-dependent sensory or sensorimotor polyneuropathy, with a “dying back” axonal pattern. Although data are sparse, for some agents this appears related to disturbances of axoplasmic flow that preferentially affect more distal axon segments (98).

Chloramphenicol. Chloramphenicol is a broad-spectrum antibiotic that inhibits protein synthesis by interfering with the 50S ribosomal subunit. It is sometimes used to treat bacterial meningitis caused by Haemophilus influenzae or Neisseria meningitides, but its use is generally limited by rare (approximately 1 in 50,000) but often fatal aplastic anemia.

Cases of neuropathy are rare, perhaps due to the typical short course of treatment, but with prolonged and high-dose therapy it can cause a mild but painful distal symmetric sensory neuropathy. Optic neuritis is more common, although in one report most patients with optic neuropathy also had evidence of peripheral neuropathy (69). Optic neuropathy has been reported with chronic chloramphenicol use in patients treated for cystic fibrosis (31). With short-term use recovery is typically full, although with prolonged use it may be incomplete (31).

Data on the pathophysiologic mechanism of nerve injury are scant. One animal study, using electron microscopy, suggested that Schwann cells and myelin rather than axons were the focus of injury; Schwann cells were hypertrophied, and myelin sheaths were swollen and fragmented, but changes in the axons were milder, showing an increase of neurofilaments and local accumulation of mitochondria (46).

Chloroquine. Chloroquine is an antiparasitic agent that prevents nucleic acid synthesis by intercalating into DNA. It is used in the treatment of malaria caused by resistant Plasmodia species, and it is also used in autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and Sjögren syndrome.

Chloroquine rarely causes a mild, sensory greater than motor distal peripheral neuropathy that appears due to both axonal damage and to demyelination (92; 97; 85). There is a single case report of paresthesias caused by the related antiparasitic mefloquine (66). The onset of neuropathy typically occurs after one or more years of use. Cerebrospinal fluid protein may be elevated, which may confuse the diagnosis with chronic inflammatory demyelinating polyneuropathy (97; 24). The major neuromuscular complication is a vacuolar myopathy (22). There are also isolated reports of chloroquine causing retinopathy and hearing loss. Marked improvement is seen on discontinuation of the drug (49; 22). Neuromuscular toxicity from short-term use of hydroxychloroquine or this agent against COVID19 is speculative at present.

Nerve biopsies have shown segmental demyelination and remyelination along with lamellar cytoplasmic inclusions in Schwann cells and perineurial cells but not in axons, all suggesting that chloroquine neuropathy is primarily due to myelin/Schwann cell damage, and not to axonal injury (49; 92).

Dapsone. Dapsone is an antiparasitic and antifungal agent that acts by inhibiting the production of folinic acid, which is required for purine and pyrimidine synthesis. Its main use is in the treatment of leprosy (Mycobacterium leprae), but it is also used for malaria (Plasmodia) and Pneumocystis carinii prophylaxis, for toxoplasmosis (Toxoplasms gondii), and to treat the rare skin condition dermatitis herpetiformis.

A rare but well-characterized, primarily motor axonal neuropathy may develop (38; 73). New cases continue to be reported (64). Patients develop progressive muscle weakness and wasting in distal muscles of the extremities, especially in the hands. It typically occurs many years after drug use, and with doses greater than 300 mg/day (96). Patients typically show complete clinical recovery, but this may be slow because it requires axonal regeneration and sprouting, and some show coasting, or clinical progression, after the drug is discontinued (45; 73). Drug-resistant leprosy strains emerged in India but only about 2% to 3% of strains are dapsone resistant (52).

The pathophysiologic mechanism of nerve injury is unknown. Abnormally slow drug metabolism by liver N-acetyltransferase has been documented in many cases, suggesting that there is a genetic predisposition to developing neuropathy due to persistent excessively high dapsone levels (45; 73; 96). Most cases of neuropathy reported are for leprosy treatment; however, one patient with pemphigus treated with dapsone is reported to have developed motor neuropathy (72). Cases of neuropathy following treatment of other dermatological problems are also known (55).

Ethambutol. Ethambutol is an antitubercular antibiotic developed in 1962 and has an unknown mechanism of action. Its use is largely confined to treating life threatening or drug resistant Mycobacterium tuberculosis, in a multidrug regimen.

A mild, predominantly sensory peripheral neuropathy is seen in as many as 4% of patients (88). It most often occurs after prolonged doses greater than 20 mg/kg/day. Optic neuropathy is more common, occurring in as many as 10% of patients treated for pulmonary tuberculosis (20). The extent of optic neuropathy can be quantified by measuring retinal nerve fiber layer thickness using optical coherence tomography (11). The risk of toxic optic neuropathy is increased in patients carrying mutation in the optic atrophy 1 (OPA1) gene, possibly through a mitochondrial toxicity mechanism (36). The peripheral neuropathy typically improves after cessation of the drug, but several reports suggest that the optic neuropathy is sometimes irreversible (88; 10; 57). Accelerated ethambutol toxic peripheral neuropathy is reported in a patient with a mitofusin 2 (MTFN2) mutation, the most common cause of axonal Charcot-Marie-Tooth disease (CMT2A). The patient developed accelerated weakness, vocal cord paralysis, and optic atrophy after receiving ethambutol (25). Interestingly, this mutation also affects mitochondrial function, namely mitochondrial fusion. After drug cessation the neuropathy stabilized and vision partially improved. Optic neuropathy is considerably more common. A well-characterized case was reported after exposure to a supratherapeutic dose (27).

The pathophysiologic mechanism of nerve damage in humans is not clear. Primary axonal injury is suggested by electrophysiologic studies, although segmental demyelination and remyelination has been reported (88). In rats given 150 mg/kg/day of ethambutol for 9 months, teased fiber analysis of lower extremity nerves showed extensive axonal degeneration and regeneration, suggesting that axonal degeneration may be primary (54).

Fluoroquinolones. Fluoroquinolones are broad-spectrum antibiotics that prevent DNA recoiling after replication by inhibiting DNA gyrase. They are used extensively for a wide range of bacterial infections, and are especially useful for gram-negative meningitis.

The evidence that fluoroquinolones might cause a peripheral neuropathy is tenuous, especially given their extensive use, but is increasingly accepted. Transient paresthesias and numbness, which resolve within a few weeks of drug discontinuation, have been reported. Other cases of multisystem and multisymptom disabling toxicity have been reported and termed mitochondrial neurogastrointestinal encephalomyopathy (33). Fluoroquinolones were first reported to cause peripheral neuropathy in a 1992 case report of a patient treated for 5 months with pefloxacin for osteomyelitis; a sensorimotor axonal polyneuropathy developed (05). Another case report describes an instance of demyelinating polyneuropathy in a patient after taking trovafloxacin (60). A study using pefloxacin to treat urinary tract infections found a single instance of transient peripheral neuropathy in 1 of 27 patients (12). However, many other studies using fluoroquinolones have not reported neuropathy as a side effect (78). A Swedish paper describes 37 patients who reported sensory disturbances to an adverse drug reaction advisory committee after having taken fluoroquinolones; over 80% described paresthesias and half described numbness; in the majority of cases, symptoms occurred within one week of starting treatment and resolved within 2 weeks after stopping the drug (40). One survey of Internet websites found that 36 of 45 of patients had severe neuropathic symptoms and in the majority of cases symptoms lasted longer than one year (17). The possible pathophysiology is unknown. Most studies, however, have limited more objective examination or electrophysiologic data. Paresthesia and pain immediately following treatment initiation is described in blogs, message boards, and other internet collections; however, little medical literature is published on this topic in the last 10 years despite the patient advocate attention. Tendinopathy is a well reported treatment complication that may have overlapping symptoms.

Despite the relatively sparse evidence of a link between fluoroquinolones and neuropathy, on August 15, 2013 the U.S. FDA announced the requirement of all makers of oral and intravenous fluoroquinolones to add the risk of the serious side effect of peripheral neuropathy (04). The decision was based on reports from the FDA’s Adverse Event Reporting System (AERS) database that serves the important function of post-marketing safety surveillance. However, the data are based on self-reports from healthcare providers, patients, and patient agents, including legal representatives; the information is not often corroborated (04). Analysis of the AERS data also found that development of Guillain-Barré syndrome and fluoroquinolones exposure, using an Empirical Bayes Geometric Mean disproportionality measure, was twice as likely (02). This support led to numerous lawsuits, including active class actions against fluoroquinolone makers, alleging that the companies withheld the risk of neuropathy. Physician reports in medicolegal journals highlight the contentious and typically anecdotal evidence (26). Etminan and colleagues attempted to better quantify this entity using a pharmacoepidemiologic approach (23). Using health claims data and identifying men coded to have neuropathy and excluding other identifiable causes of neuropathy, mainly diabetes and heredity, the authors compared exposure to fluoroquinolones against a larger control group. An increased incidence of neuropathy was found in the treated group leading to the conclusion that there is an increased risk of neuropathy with oral fluoroquinolone use; a higher incidence was found with current drug use. There appears to be a clear link to drug initiation and neuropathic symptoms that often persist; however, the true incidence and neurologic impact remains to be determined (84). A United Kingdom group performed a very large case-control study mining data from a primary care database in the United Kingdom (58). The cohort of over 1.3 million adults was issued prescriptions for a fluoroquinolone (34.3%) or amoxicillin-clavulanate (65.7%) antibiotic. Patients coded to have neuropathy were matched with controls treated with the same antibiotics but were not coded to have neuropathy. Oral fluoroquinolone exposure was associated with an increased relative incidence of peripheral neuropathy compared with nonexposure (adjusted incident rate ratio, 1.47; 95% CI, 1.13-1.92); amoxicillin-clavulanate exposure had no increased risk. They noted a 10-day treatment of over 150,000 patients was needed to produce one additional neuropathy case. Fluoroquinolone prophylaxis was studied in 598 children with acute lymphoblastic leukemia that also received vincristine. There was no significant difference in chemotherapy neuropathy rates between those exposed to fluoroquinolones and those who were not (43). Care should be taken with drug use in this class of patients that already know they have symptomatic neuropathy. A Cochrane style review of toxicity and safety in diabetic patients found 16 of 725 studies met search criteria (03). Fourteen studies address hyperglycemia, and only two address neuropathy. They concluded that further research was needed for this suspected association. An interesting claims data review from a commercial insurance cohort reviewed registered central and peripheral nervous system symptoms related to fluoroquinolone usage (21). Their cohort contained 976,568 individuals exposed to a fluoroquinolone antibiotic matched 1:1 with a comparator antibiotic for common infections. The fluoroquinolone exposure hazard ratio was 1.08, more commonly peripheral than central. Isolated case reports continue to be uncovered. A 13-year-old teen developed acute neuropathic symptoms on ciprofloxacin that abated after withdrawal (59). Additional temporally linked cases continue to be reported (70).

Isoniazid. Isoniazid has been used to prevent tuberculosis (Mycobacterium tuberculosis) since the early 1950s. It works by an unknown but specific mechanism.

Although hepatitis is the most dangerous adverse effect of isoniazid, peripheral neuropathy is the most common; it occurs in 1% to 3% of patients receiving conventional doses of 3 to 5 mg/kg per day (09). Isoniazid causes a predominantly sensory, predominantly large-fiber symmetric axonal peripheral neuropathy (15). Initially, patients describe distal tingling paresthesias and numbness in the feet. Occasionally, numbness can have a burning quality that can be severe. If untreated, symptoms may ascend to the knees and spread to the hands, and weakness can develop. Symptoms typically occur after several months of treatment (32). Recovery is rapid if the problem is detected early but may be slow and incomplete if the cause remains unrecognized. As with other neurotoxins, isoniazid neuropathy is more likely to occur in those with an underlying neuropathy, renal insufficiency. HIV-infected patients are at increased neuropathy risk prior to initiation of treatment if they were treated for tuberculosis; in a study, many were pyridoxine deficient (93). Additionally, isoniazid is acetylated in the liver by N-acetyltransferase, and those who carry mutations in N-acetyltransferase leading to slow acetylation are at increased risk for neuropathy (32).

Isoniazid is an antagonist of pyridoxine (vitamin B6), a coenzyme essential for protein, carbohydrate and fatty acid metabolism; it causes a functional pyridoxine deficiency, which is regarded as the underlying cause of the peripheral neuropathy. Daily pyridoxine supplementation (10 to 100 mg/day) protects against the development of neuropathy. In rats given toxic doses of isoniazid, teased nerve fiber studies are consistent with a “dying back” distal axonopathy, with sparing of cell bodies (15). Other medications that likely produce neuropathy by similar pyridoxine mechanisms include phenytoin and phenelzine. Sensory and motor neuropathy has also been reported in a patient on high-dose isoniazid (5 mg/kg/day) without pyridoxine supplements; she partially improved after pyridoxine supplement despite isoniazid continuation (06). Isoniazid use in HIV patients in tuberculosis endemic areas is increasingly advocated for increased scale (61). A cross sectional questionnaire-based study of isoniazid preventive therapy in HIV patients in Uganda examined symptoms in 660 patients. The agent is intended to prevent latent tuberculosis reactivation. About half had suspected isoniazid adverse drug reactions; 11% were labeled as neuropathy (62). Dizziness and musculoskeletal symptoms were similar incidence.

Linezolid. Linezolid, first approved in 2000, is a synthetic oxazolidinone antibiotic used against methicillin-resistant and vancomycin-resistant gram-positive microorganisms and increasingly against multidrug-resistant tuberculosis (77). It binds to the 50S ribosomal subunit and prevents the formation of the initiation complex required to translate mRNA into protein. Linezolid was recently reclassified as a Group A drug by the World Health Organization (WHO) for treatment of multi-drug resistant tuberculosis (79).

Linezolid can cause a predominantly sensory axonal neuropathy and neuronopathy when used for months and at a high dose (71; 102; 95). Vibration and proprioception senses are severely affected (102). Chronic use is associated with a painful, predominantly sensory polyneuropathy, optic neuropathy, and deafness (71; 13; 39). Only minor adverse effects were seen in phase III trials; however, several more serious adverse effects were reported after commercial release, including cases of lactic acidosis, peripheral and optic neuropathy, and serotonin syndrome (63). Abnormalities of nerve conduction studies and diminished epidermal nerve fiber density are reported (71; 13). The optic neuropathy is usually reversible after discontinuing the drug (56; 76), but it can be irreversible (07). A case noting reversibility is also reported (94). The peripheral sensory loss is often permanent (82; 102; 95), or it may partially reverse (13). The antibiotic is increasingly used against treatment-resistant tuberculosis. A meta-analysis of available data from multiple registries found neuropathy and anemia to be the most common toxicities; overall neuropathy occurred in 31% on chronic therapy (101). A 15-year-old boy from Tajikistan had 5 years of type I diabetes but no symptomatic neuropathy (87). He contracted multidrug resistant tuberculosis and was treated with a cocktail containing linezolid 600 mg daily. After 8 months he developed symptomatic and electrodiagnostic neuropathy. He improved after drug cessation and was asymptomatic after 21 months. The underlying role of diabetes was raised. A simulation model based on reports of 104 participations found that significant neuropathy differed between 600 and 1200 mg daily linezolid doses used against drug-resistant tuberculosis (41). Neuropathy typically appeared 3 to 6 months after treatment onset. Anemia appeared to also be dose dependent, but thrombocytopenia was not. A 3-center retrospective study of 184 patients treated with linezolid for rifampicin-resistant tuberculosis found 28% reported neuropathy symptoms; median symptom onset time was 45 days after treatment initiation (18). Hemochromatosis occurred in 23% in this cohort.

The mechanism of nerve injury is unknown but may be impairment of mitochondrial protein synthesis (74). There is no recognized treatment other than symptomatic measures and discontinuation of the drug or decreasing the dose (44). Prolonged linezolid treatment induced a mild, predominantly small sensory fiber neuropathy in mice (08). Linezolid exposure caused mitochondrial dysfunction primarily in cultured sensory neurons and less prominently in Schwann cells. Sensory axonopathy could be partially prevented by co-administration of the Na(+)/Ca(2+) exchanger blocker KB-R7943. Linezolid treatment of multidrug-resistant tuberculosis is limited by neuropathy. The drug caused loss of neurons, myelin, and increased autophagy indicators in a rat model and suppression of Schwann cells in an in vitro model (100).

Linezolid continues to be employed to treat antibiotic resistant tuberculosis. A Korean group studied 94 cases of chronic high and low linezolid treatment for multi-drug resistant tuberculosis. There was benefit for tuberculosis suppression but no difference in outcome in high and low dose groups. Neuropathy was the most common complication even in the low dose group, noted in 48% (16). An Indian group studied 165 tuberculosis-resistant patients treated with chronic linezolid. Sixty-nine developed neuropathy (40%). Pharmacokinetic measures at 2 points found higher drug levels at week 16 compared to week 8 despite fixed dosage. Neuropathy was also associated with higher serum trough levels (68).

Metronidazole. Metronidazole is a broad-spectrum antibiotic that binds to DNA and blocks replication. It is effective against protozoa (eg, Trichomonas, Giardia, Entamoeba), bacteria (Clostridium difficile, Helicobacter pylori), parasites (Trichomonas vaginalis), and microsporidia. It is also used chronically in the treatment of inflammatory bowel disease.

Metronidazole carries a low but well-documented risk of sensory neuropathy, especially after months to years of use and with cumulative doses exceeding 30g (103). A distal pansensory neuropathy characterized by pain, burning paresthesias, and dysesthesias in the feet and hands is typical. Improvement may take months once the drug is stopped. Additional cases continue to be reported (80).

Little is known about the etiology and pathogenesis of metronidazole neurotoxicity. A sural biopsy study revealed that myelinated fibers appear preferentially affected, although on electron microscopy unmyelinated axons also showed degeneration (89). The pathogenesis of metronidazole peripheral nerve injury is largely inferred from studies of misonidazole, a related compound that is used as a chemotherapeutic adjunct to sensitize hypoxic cells to the effects of ionizing radiation. As with metronidazole, misonidazole neurotoxicity consists of a predominantly sensory polyneuropathy, with pain and distal burning dysesthesias. Animal studies show distal axonal degeneration, especially sensory terminals and in intramuscular fibers, and studies in cultured neuronal cell suggest that the mechanism may be disruption and degradation of the neurofilament lattice (35; 86). Other postulated mechanisms include impaired membrane transport and inhibition of protein synthesis (53). Skin biopsy of epidermal nerve fiber density is another means to document the toxic effect of prolonged exposure. Serial skin biopsies demonstrated emergence of painful sensory neuropathy in a 53-year-old man treated with metronidazole at a cumulative dose of 146 g over 88 days (90). A metanalysis based on available published reports intended to guide clinical practice concluded that incidence was rare if dose was below 42 g total and less than four weeks duration (34). However, cases starting very soon after drug initiation are reported (65). A Canadian group conducted a population-based nested case control study of adults admitted for various neurologic conditions including neuropathy whom also received a metronidazole or clindamycin prescription within 100 days of admission—1212 cases were identified (19). A conditional logistic regression model was used to estimate relative risk. A relative increased risk of 1.34 was found after adjusting for other factors. Rates of central and peripheral nerve toxicity were similar. A 69-year-old woman treated with a total of 55 g of metronidazole for diverticular disease and a 52-year-old man with a protracted metronidazole course for a hepatic abscess (cumulative dose 168 g) developed peripheral neuropathy (37). Of note, metronidazole can be used without physician direction in some countries. An Indian man developed neuropathy after extended metronidazole self-treatment for a suspected amebic disorder (28). He also had increased signal in the splenium of the corpus callosum (boomerang sign), presumed to be cytotoxic edema. The splenium lesion resolved, and the neuropathy improved after drug cessation.

Nitrofurantoin. Nitrofurantoin is a broad-spectrum antibiotic approved in 1953 that disrupts bacterial cell wall formation and may inhibit RNA and DNA synthesis. It is occasionally used to treat urinary tract infections. It has no systemic antibacterial effect because its activity depends on its being concentrated in the urine; it is, therefore, ineffective in renal failure.

Nitrofurantoin causes a symmetric, motor greater than sensory axonal neuropathy, characterized by distal weakness, paresthesias, and numbness. It may arise acutely and within weeks to months of starting the drug, and may be unrelated to dose (99). Renal insufficiency or failure appears to predispose to neuropathy, possibly due to concomitant excessive tissue concentrations (51). Recovery may be slow, partial and unrelated to cumulative dose (99).

An early histologic study showed axonal degeneration and chromolysis in anterior horn cells (50). A second histologic study using both light microscopy and electron micrography was consistent with severe axonal degeneration (99). It has been postulated that neurotoxicity may be due to a dose-dependent depletion of glutathione (83). In addition, cases of small fiber sensory and painful neuropathy are recognized. Morphological changes, such as clustered terminal nerve swellings, in skin biopsy samples demonstrated support of two cases of clinical nitrofurantoin-induced neuropathy despite normal sensory and motor nerve conduction studies (91). A lone case of nitrofurantoin-triggered vasculitic neuropathy is reported. A 60-year-old woman developed severe axonal neuropathy after starting nitrofurantoin; superficial radial nerve biopsy demonstrated vasculitis (01).

A group reviewed about 10 years of reports to the Korea Adverse Event Reporting System (KAERS) database (48). They found over 92,000 metronidazole treated patients, likely most with short treatment courses. Twenty-eight listed neuropathy as the adverse reported event. Cirrhosis, renal disease, intravenous administration, and low body weight were associated factors.

Suramin. Suramin is a polysulfonated naphthylurea that is not approved in the United Stated, but which is used as an antiprotozoal antibiotic to prophylaxis against sleeping sickness (Trypanosoma sp). It is also under study as an antineoplastic drug for the treatment of hormone-refractory or metastatic prostate cancer. The primary factor limiting its use is toxic neuropathy.

Up to 50% of patients develop a mild symmetric distal sensorimotor axonal polyneuropathy (14). The risk appears much greater if serum concentrations are greater than 350 mg/ml, and appear unrelated to cumulative dose or duration of treatment (81; 29). Patients typically report burning paresthesias, which usually involve the distal extremities but occasionally also involve the face; distal weakness may follow, and occasionally this may be more proximal than distal. A minority of patients develop a subacute and progressive demyelinating polyneuropathy similar to Guillain-Barré syndrome (14; 81). There are some reports of severe symptoms, with bulbar weakness, respiratory weakness, and even dysautonomia (47; 29). In those with demyelination, cerebrospinal fluid protein is elevated; patients have improved with plasmapheresis (14).

Human electrophysiologic studies show both axonal and demyelinating neuropathy (14; 81). Sural nerve specimens have has shown lymphocytic infiltrates (14). In rats, one sees a length- and dose-dependent axonal sensorimotor polyneuropathy with an accumulation of lysosomal ceramide inclusions (29; 75). Postulated pathophysiologic mechanisms include disruption of glycolipid metabolism leading to apoptosis, disruption of calcium signaling via antagonism of purinergic receptors, and inhibition of mitogenic growth receptors (29; 30; 67).

Overall, the detailed cell-biological and biochemical basis for the antibiotic-induced neuropathies is poorly understood. However, the susceptibility of peripheral nerves to toxic injury may be related to the relatively leaky blood-peripheral nerve barrier; drugs can, thus, more readily reach peripheral nerve, dorsal root and autonomic ganglia, compared to spinal cord or other central nervous system neurons (42; 98).

References

01: Aladawi M, Shelly S, Dyck PJB, et al. Nitrofurantoin and minocycline-associated vasculitic neuropathy: case reports and literature review. J Clin Neuromuscul Dis 2022;24(2):85-94. PMID 36409339
02: Ali AK. Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. Ann Epidemiol 2014;24(4):279-85. PMID 24472364
03: Althaqafi A, Ali M, Alzahrani Y, Ming LC, Hussain Z. How safe are fluoroquinolones for diabetic patients? A systematic review of dysglycemic and neuropathic effects of fluoroquinolones. Ther Clin Risk Manag 2021;17:1083-90. PMID 34675522
04: Anonymous. Fluoroquinolones and peripheral neuropathy. Med Lett Drugs Ther 2013;55(1429):89. PMID 24220576
05: Aoun M, Jacquy C, Debusscher L, et al. Peripheral neuropathy associated with fluoroquinolones. Lancet 1992;340:127. PMID 1352007
06: Arsalan R, Sabzwari S. Isoniazid induced motor-dominant neuropathy. J Pak Med Assoc 2015;65(10):1131-3. PMID 26440850
07: Azamfirei L, Copotoiu SM, Branzaniuc K, Szederiesi J, Copotoiu R, Berteanu C. Complete blindness after optic atrophy induced by short-term linezolid treatment in a patient suffering from muscle dystrophy. Pharmacoepidemiol Druf Saf 2007;16(4):402-4. PMID 16998949
08: Bobylev I, Maru H, Joshi AR, Lehmann HC. Toxicity to sensory neurons and Schwann cells in experimental linezolid-induced peripheral neuropathy. J Antimicrob Chemother 2016;71(3):685-91. PMID 26612872
09: Bosch EP, Smith BE. Disorders of peripheral nerves. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, editors. Neurology in clinical practice. 3rd edition. Boston: Butterworth-Heinemann, 2000:2045-130.
10: Carelli V, Ross-Cisneros FN, Sadun AA. Optic nerve degeneration and mitochondrial dysfunction: genetic and acquired optic neuropathies. Neurochem Int 2002;40(6):573-84. PMID 11850115
11: Chai SJ, Foroozan R. Decreased retinal fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy. Br J Ophthalmol 2007;91(7):895-7. PMID 17215265
12: Chan PC, Cheng IK, Chan MK, Wong WT. Clinical experience with pefloxacin in patients with urinary tract infections. Br J Clin Pract 1990;44:564-7. PMID 2102145
13: Chao CC, Sun HY, Chang YC, Hsieh ST. Painful neuropathy with skin denervation after prolonged use of linezolid. J Neurol Neurosurg Psychiatry 2008;79(1):97-9. PMID 17766431
14: Chaudhry V, Eisenberger MA, Eisenberger MA, et al. A prospective study of suramin-induced peripheral neuropathy. Brain 1996;119:2039-52. PMID 9010008
15: Chua CL, Ohnishi A, Tateishi J, Kuroiwa Y. Morphometric evaluation of degenerative and regenerative changes in isoniazid-induced neuropathy. Acta Neuropathol 1983;60(3-4):183-93. PMID 6310925
16: Chung C, Jo KW, Shim TS. Treatment outcome, recurrence and safety of multidrug-resistant TB treated with low-dose linezolid. Int J Tuberc Lung Dis 2023;27(12):918-24. PMID 38042970
17: Cohen JS. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother 2001;35:1540-7. PMID 11793615
18: Cui D, Hu X, Shi L, Wang D, Chen G. Linezolid-related adverse effects in the treatment of rifampicin resistant tuberculosis: a retrospective study. J Chemother 2022:1-7. PMID 36322121
19: Daneman N, Cheng Y, Gomes T, et al. Metronidazole-associated neurologic events: a nested-case control study. Clin Infect Dis 2021;72(12):2095-100. PMID 32303736
20: De Palma P, Franco F, Bragliani G, et al. The incidence of optic neuropathy in 84 patients treated with ethambutol. Metab Pediatr Syst Ophthalmol 1989;12(1-3):80-2. PMID 2770528
21: Ellis DE, Hubbard RA, Willis AW, et al. Comparative neurological safety of fluoroquinolones versus therapeutic alternatives. Pharmacoepidemiol Drug Saf 2021;30(6):797-805. PMID 33655544
22: Estes ML, Ewing-Wilson D, Chou SM, et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 1987;82(3):447-55. PMID 3826099
23: Etminan M, Brophy JM, Samii A. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology 2014;83(14):1261-3. PMID 25150290
24: Finsterer J, Jarius C. Increased CSF protein in chloroquine-induced axonal polyneuropathy and myopathy. Clin Neurol Neurosurg 2003;105:231-6. PMID 12954536
25: Fonkem E, Skordilis MA, Binkley EM, et al. Ethambutol toxicity exacerbating the phenotype of CMT2A2. Muscle Nerve 2013;48(1):140-4. PMID 23733358
26: Francis JK, Higgins E. Permanent peripheral neuropathy: a case report on a rare but serious debilitating side-effect of fluoroquinolone administration. J Investig Med High Impact Case Rep 2014;2(3):2324709614545225. PMID 26425618
27: Geyer HL, Herskovitz S, Slamovits TL, Schaumburg HH. Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment. J Neuroophthalmol 2014;34(3):257-8. PMID 24897009
28: Ghosh R, Chatterjee S, Dubey MJ, Dubey S, Benito-León J. Metronidazole-induced toxic neuropathy with the "Boomerang" sign: a case report. Clin Neuropharmacol 2022;45(2):35-8. PMID 35195547
29: Gill JS, Windebank AJ. Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ 1998a;5(10):876-83. PMID 10203686
30: Gill JS, Windebank AJ. Direct activation of the high-affinity nerve growth factor receptor by a non-peptide symmetrical polyanion. Neuroscience 1998b;87(4):855-60. PMID 9759973
31: Godel V, Nemet P, Lazar M. Chloramphenicol optic neuropathy. Arch Ophthalmol 1980;98:1417-21. PMID 7417077
32: Goel UC, Bajaj S, Gupta OP, Dwivedi NC, Dubey AL. Isoniazid induced neuropathy in slow versus rapid acetylators: an electrophysiological study. J Assoc Physicians India 1992;40(10):671-2. PMID 1339149
33: Golomb BA, Koslik HJ, Redd AJ. Fluoroquinolone-induced serious, persistent, multisymptom adverse effects. BMJ Case Rep 2015;2015. PMID 26438672
34: Goolsby TA, Jakeman B, Gaynes RP. Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature. Int J Antimicrob Agents 2018;51(3):319-25. PMID 28887203
35: Griffin JW, Price DL, Kuerthe DO, Goldberg AM. Neurotoxicity of misonidazole in rats. I. Neuropathology. Neurotoxicology 1979;1:299.
36: Guillet V, Chevrollier A, Cassereau J, et al. Ethambutol-induced optic neuropathy linked to OPA1 mutation and mitochondrial toxicity. Mitochondrion 2010;10(2):115-24. PMID 19900585
37: Gussago S, Poroli Bastone C, Celio D, Arigoni M, Quarenghi MC. Metronidazole and peripheral neuropathy: a report of two cases of (Unusual) side effects. Cureus 2022;14(10):e30889. PMID 36465791
38: Gutmann L, Martin JD, Welton W. Dapsone motor neuropathy--an axonal disease. Neurology 1976;26:514-6. PMID 945490
39: Heckmann JG, Dutsch M, Schwab S. Linezolid-associated small-fiber neuropathy. J Peripher Nerv Syst 2008;13(2):157-8. PMID 18601662
40: Hedenmalm K, Spigset O. Peripheral sensory disturbances related to treatment with fluoroquinolones. J Antimicrob Chemother 1996;37:831-7. PMID 8722551
41: Imperial MZ, Nedelman JR, Conradie F, Savic RM. Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis. Clin Infect Dis 2021:ciab699. PMID 34604901
42: Jain KK. Drug-induced peripheral neuropathies. In: Jain KK, editor. Drug-Induced Neurological Disorders. 2nd edition. Seattle: Hogrefe & Huber, 2001:263-94.
43: Karol SE, Sun Y, Tang L, et al. Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. Cancer Med 2020;9(18):6550-5. PMID 32710497
44: Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009;64(2):388-91. PMID 19468028
45: Koller WC, Gehlmann LK, Malkinson FD, Davis FA. Dapsone-induced peripheral neuropathy. Arch Neurol 1977;34:644-6. PMID 199146
46: Kuroda S, Tateishi J, Otsuki S. Neurotoxicity with chloramphenicol--an electron microscopic study. Folia Psychiatr Neurol Jpn 1975;29:39-46. PMID 1158315
47: La Rocca RV, Meer J, Gilliatt RW, et al. Suramin-induced polyneuropathy. Neurology 1990;40(6):954-60. PMID 2161094
48: Lee SJ, Kim J, Lee KH, et al. Frequency and risk factor analysis for metronidazole-associated neurologic adverse events. J Gen Intern Med 2023. [Epub ahead of print] PMID 38093026
49: Leger JM, Puifoulloux H, Dancea S, et al. Chloroquine neuromyopathies: 4 cases during antimalarial prevention. Rev Neurol (Paris) 1986;142:746-52. PMID 3029852
50: Lhermitte F, Fritel D, Cambier J. Polynevrites au cours de traitments par la nitrofurantoine. Presse Med 1963;71:767-70. PMID 13930375
51: Loughridge LW. Peripheral neuropathy due to nitrofurantoin. Lancet 1962;2:1133.
52: Mahajan NP, Lavania M, Singh I, et al. Evidence for Mycobacterium leprae drug resistance in a large cohort of leprous neuropathy patients from India. Am J Trop Med Hyg 2020;102(3):547-52. PMID 31933458
53: Mamoli B, Wessely P, Kogelnik HD, Muller M, Rathkolb O. Electroneurographic investigations of misonidazole polyneuropathy. Eur Neurol 1979;18:405-14. PMID 232682
54: Matsuoka Y, Takayanagi T, Sobue I. Experimental ethambutol neuropathy in rats. Morphometric and teased-fiber studies. J Neurol Sci 1981;51:89-99. PMID 6265603
55: McCarty M. How clinically relevant is dapsone-related peripheral neuropathy.: An overview of available data with emphasis on clinical recognition. J Clin Aesthet Dermatol 2010;3(3):19-21. PMID 20725539
56: McKinley SH, Foroozan R. Optic neuropathy associated with linezolid treatment. J Neuroophthalmol 2005;25:18-21. PMID 15756127
57: Melamud A, Kosmorsky GS, Lee MS. Ocular ethambutol toxicity. Mayo Clin Proc 2003;78:1409-11. PMID 14601701
58: Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X. Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy. JAMA Neurol 2019;76(7):827-33. PMID 31034074
59: Morley C, Carvalho de Almeida C, Moloney S, Grimwood K. Ciprofloxacin-associated peripheral neuropathy in a child: A case report and review of the literature. Pediatr Infect Dis J 2022;41(2):121-2. PMID 34817415
60: Murray CK, Wortmann GW. Trovafloxacin-induced weakness due to a demyelinating polyneuropathy. South Med J 2000;93:514-5. PMID 10832955
61: Nabity SA, Gunde LJ, Surie D, et al. Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017). PLoS One 2021;16(4):e0248115. PMID 33793577
62: Nanyonga SM, Kitutu FE, Kalyango J, Frank M, Kiguba R. High burden of adverse drug reactions to Isoniazid Preventive Therapy in people living with HIV at three tertiary hospitals in Uganda: associated factors. J Acquir Immune Defic Syndr 2022;89(2):215-21. PMID 34693930
63: Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007;27(8):1189-97. PMID 17655517
64: Nguyen GH, Guo EL, Norris D. A rare case of erythema elevatum diutinum presenting as diffuse neuropathy. JAAD Case Rep 2016;3(1):1-3. PMID 28050587
65: Oaku T, Yamada N, Ikeda K, et al. Early onset of metronidazole-induced peripheral neuropathy in a patient with amoebic colitis:a case report. Nihon Shokakibyo Gakkai Zasshi 2020;117(1):72-7. PMID 31941859
66: Olson PE, Kennedy CA, Morte PD. Paresthesias and mefloquine prophylaxis. Ann Intern Med 1992;117:1058-9. PMID 1443980
67: Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249:9-17. PMID 11954874
68: Padmapriyadarsini C, Solanki R, Jeyakumar SM, et al. Linezolid pharmacokinetics and its association with adverse drug reactions in patients with drug-resistant pulmonary tuberculosis. Antibiotics (Basel) 2023;12(4):714. PMID 37107075
69: Ramilo O, Kinane BT, McCracken GH Jr. Chloramphenicol neurotoxicity. Pediatr Infect Dis J 1988;7:358-9. PMID 3380586
70: Refaeian A, Vest EL, Schmidt M, et al. Ciprofloxacin-induced peripheral neuropathy: a case report. HCA Healthc J Med 2023;4(5):383-7. PMID 37969850
71: Rho JP, Sia IG, Crum BA, Dekutoski MB, Trousdale RT. Linezolid-associated peripheral neuropathy. Mayo Clin Proc 2004;79:927-30. PMID 15244392
72: Rhodes LE, Coleman MD, Lewis-Jones MS. Dapsone-induced motor peripheral neuropathy in pemphigus foliaceus. Clin Exp Dermatol 1995;20(2):155-6. PMID 8565254
73: Rosen I, Sornas R. Peripheral motor neuropathy caused by excessive intake of dapsone (Avlosulfon). Arch Psychiatr Nervenkr 1982;232(1):63-9. PMID 6293406
74: Rucker JC, Hamilton SR, Bardenstein D, Isada CM, Lee MS. Linezolid-associated toxic optic neuropathy. Neurology 2006;66(4):595-8. PMID 16505322
75: Russell JW, Gill JS, Sorenson EJ. Suramin-induced neuropathy in an animal model. J Neurol Sci 2001;192:71-80. PMID 11701155
76: Saijo T, Hayashi K, Yamada H, Wakakura M. Linezolid-induced optic neuropathy. Am J Ophthalmol 2005;139:1114-6. PMID 15953450
77: Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010;50(1):49-55. PMID 19947856
78: Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7(4):301-5. PMID 11720319
79: Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2019;3:CD012836. PMID 30893466
80: Soh Y. Metronidazole-induced recurrent paresthesia: A case report. Neurol India 2021;69(1):174-6. PMID 33642295
81: Soliven B, Dhand UK, Kobayashi K, et al. Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve 1997;20(1):83-91. PMID 8995587
82: Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 2004;54:832-5. PMID 15317746
83: Spielberg SP, Gordon GB. Nitrofurantoin cytotoxicity. In vitro assessment of risk based on glutathione metabolism. J Clin Invest 1981;67(1):37-41. PMID 7451657
84: Staff NP, Dyck PJB. On the association between fluoroquinolones and neuropathy. JAMA Neurol 2019;76(7):753-4. PMID 31034010
85: Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000;27(12):2927-31. PMID 11128688
86: Stevenson MA, Calderwood SK, Coleman CN. Effects of nitroimidazoles on neuronal cells in vitro. Int J Radiat Oncol Biol Phys 1989;16:1225-30. PMID 2523881
87: Swaminathan A, du Cros P, Seddon JA, et al. Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature. BMC Infect Dis 2017;17(1):417. PMID 28606115
88: Takeuchi H, Takahashi M, Kang J, et al. Ethambutol neuropathy: clinical and electroneuromyographic studies. Folia Psychiatr Neurol Jpn 1980;34(1):45-55. PMID 6248440
89: Takeuchi H, Yamada A, Touge T, Miki H, Nishioka M, Hashimoto S. Metronidazole neuropathy: a case report. Jpn J Psychiatry Neurol 1988;42:291-5. PMID 2853804
90: Tan CH, Chen YF, Chen CC, et al. Painful neuropathy due to skin denervation after metronidazole-induced neurotoxicity. J Neurol Neurosurg Psychiatry 2011;82(4):462-5. PMID 20551481
91: Tan IL, Polydefkis MJ, Ebenezer GJ, et al. Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol 2012;69(2):265-8. PMID 22332195
92: Tegner R, Tome FM, Godeau P, Lhermitte F, Fardeau M. Morphological study of peripheral nerve changes induced by chloroquine treatment. Acta Neuropathol 1988;75:253-60. PMID 2831692
93: van der Watt JJ, Benatar MG, Harrison TB, Carrara H, Heckmann JM. Isoniazid exposure and pyridoxine levels in human immunodeficiency virus associated distal sensory neuropathy. Int J Tuberc Lung Dis 2015;19(11):1312-9. PMID 26467583
94: Vishnu VY, Modi M, Goyal MK, Lal V. Linezolid induced reversible peripheral neuropathy. Am J Ther 2016;23(6):e1839-e1841. PMID 26741956
95: von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases. J Infect 2006;52(2):92-6. PMID 15907341
96: Waldinger TP, Siegle RJ, Weber W, Voorhees JJ. Dapsone-induced peripheral neuropathy. Case report and review. Arch Dermatol 1984;120:356-9. PMID 6322702
97: Wasay M, Wolfe GI, Herrold JM, Burns DK, Barohn RJ. Chloroquine myopathy and neuropathy with elevated CSF protein. Neurology 1998;51:1226-7. PMID 9781573
98: Weimer LH. Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2003;3(1):86-92. PMID 12507417
99: Yiannikas C, Pollard JD, McLeod JG. Nitrofurantoin neuropathy. Aust N Z J Med 1981;11(4):400-5. PMID 6272676
100: Yuan Y, Li J, Chen Y, et al. Mechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis. Front Pharmacol 2022;13:946058. PMID 36160387
101: Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis 2015;7(4):603-15. PMID 25973226
102: Zivkovic SA, Lacomis D. Severe sensory neuropathy associated with long-term-linezolid use. Neurology 2005;64:926-7. PMID 15753447
103: Zivkovic SA, Lacomis D, Giuliani MJ. Sensory neuropathy associated with metronidazole: report of four cases and review of the literature. J Clin Neuromuscul Disord 2001;3:8-12. PMID 19078646

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male=female
Heredity: heredity may be a factor
Population groups selectively affected: none
Occupation groups selectively affected: none

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Antibiotic-induced neuropathy

Differential Diagnosis

other causes of axonal polyneuropathy
other causes of demyelinating polyneuropathy

Also Relevant

Clinical evaluation of peripheral neuropathies
Drug-induced neuropathies

Clinical Categories

Peripheral Neuropathies

Antibiotic-induced neuropathy …

Antibiotic-induced neuropathy

Introduction

Overview

Historical note and terminology

Table 1. Antimicrobials Associated with Peripheral Neuropathy

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

References

Contributors

Author

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Familial dysautonomia

Peripheral nerve complications of HIV-1 infection

Neuropathies associated with cytomegalovirus infection

Disulfiram neuropathy

Mercury neuropathy

Clinical evaluation of peripheral neuropathies

Carpal tunnel syndrome

Antibiotic-induced neuropathy

Introduction

Overview

Historical note and terminology

Table 1. Antimicrobials Associated with Peripheral Neuropathy

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

References

Contributors

Author

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Familial dysautonomia

Peripheral nerve complications of HIV-1 infection

Neuropathies associated with cytomegalovirus infection

Disulfiram neuropathy

Mercury neuropathy

Clinical evaluation of peripheral neuropathies

Carpal tunnel syndrome

This is an article preview.
Start a Free Account
to access the full version.